0001104659-23-070046.txt : 20230609
0001104659-23-070046.hdr.sgml : 20230609
20230609180525
ACCESSION NUMBER: 0001104659-23-070046
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230608
FILED AS OF DATE: 20230609
DATE AS OF CHANGE: 20230609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hamill Laura
CENTRAL INDEX KEY: 0001751804
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38650
FILM NUMBER: 231006624
MAIL ADDRESS:
STREET 1: 333 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc.
CENTRAL INDEX KEY: 0001722964
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474619612
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 230 PARK AVENUE
STREET 2: SUITE 3350
CITY: NEW YORK
STATE: NY
ZIP: 10169
BUSINESS PHONE: 212-847-9841
MAIL ADDRESS:
STREET 1: 230 PARK AVENUE
STREET 2: SUITE 3350
CITY: NEW YORK
STATE: NY
ZIP: 10169
4
1
tm2318348-6_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-06-08
0
0001722964
Y-mAbs Therapeutics, Inc.
YMAB
0001751804
Hamill Laura
C/O Y-MABS THERAPEUTICS, INC.
230 PARK AVENUE SUITE 3350
NEW YORK
NY
10169
1
0
0
0
0
Common Stock
2023-06-08
4
A
0
2330
0
A
2330
D
Employee Stock Option (right to buy)
8.13
2023-06-08
4
A
0
13950
0
A
2033-06-08
Common stock
13950
13950
D
Represents restricted stock units ("RSUs") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2024, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on the vesting date.
Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on each vesting date and are exercisable immediately upon vesting.
/s/ Sune Reinholth Nyland, Attorney-in-Fact for Laura Hamill
2023-06-09